GFR, Albuminuria & Beyond: Paving the Way to Validation of Early Biomarkers of Disease Progression & Therapeutic Efficacy

Time: 8:30 am
day: Day One


  • Where are we now? Interrogating changes in GFR and albuminuria as early biomarkers and surrogate endpoints in rare and inherited renal disorders
  • Validating biomarkers in large cohort studies to deeply characterize disease etiology and progression
  • Stronger together: promoting sharing of biosamples and advancing centralized biobanks